Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0065)
Name
Phenethyl isothiocyanate
Synonyms
2-Phenylethyl isothiocyanate; Phenethyl isothiocyanate; 2257-09-2; Phenylethyl isothiocyanate; (2-Isothiocyanatoethyl)benzene; Benzene, (2-isothiocyanatoethyl)-; PEITC; Phenylaethylsenfoel; 2-isothiocyanatoethylbenzene; ISOTHIOCYANIC ACID, PHENETHYL ESTER; PHENETHYLISOTHIOCYANATE; phenethyl-isothiocyanate; beta-Phenylethyl isothiocyanate; .beta.-Phenylethyl isothiocyanate; CHEBI:351346; NSC 87868; 2-phenylethylisothiocyanate; 6U7TFK75KV; beta-Phenethyl isothiocyanate; CHEMBL151649; .beta.-Phenethyl isothiocyanate; 1-Isothiocyanato-2-phenylethane; DTXSID5021120; NSC-87868; Isothiocyanic Acid 2-Phenylethyl Ester; JC-5411; MFCD00004821; Phenylaethylsenfoel [German]; 1-ISOTHIOCYANATO-2-PHENYLETHANE (1,1,2,2-D4); CCRIS 3146; EINECS 218-855-5; BRN 2084162; WLN: SCN2R; ss-Phenethyl isothiocyanate; Epitope ID:138724; UNII-6U7TFK75KV; 2-phenyl ethyl isothiocyanate; SCHEMBL156960; Phenethyl isothiocyanate, 99%; DTXCID901120; FEMA NO. 4014; IZJDOKYDEWTZSO-UHFFFAOYSA-; (2-Isothiocyanato-ethyl)-benzene; (2-Isothiocyanatoethyl)benzene #; 1-(2-isothiocyanatoethyl)benzene; 2-Phenylethyl isothiocyanate, FG; HMS1783C17; HMS3870G13; NSC87868; Tox21_200100; (2-Isothiocyanatoethyl)benzene, 9CI; BBL009999; BDBM50240850; JC5411; PHENETHYL ISOTHIOCYANATE [MI]; STK397325; AKOS000119469; DB12695; JC 5411; JC 5411JC-5411; NCGC00248526-01; NCGC00257654-01; PHENYLETHYL ISOTHIOCYANATE [FHFI]; AC-12769; AS-17373; BP-12941; HY-23155; NCI60_041942; CAS-2257-09-2; Isothiocyanic acid .beta.-phenylethyl ester; FT-0604634; P0986; Phenethyl isothiocyanate, analytical standard; EN300-17386; D92051; 4-12-00-02476 (Beilstein Handbook Reference); A816267; J-802164; Q7181339; W-107466; BRD-K56700933-001-02-1; Z56924472; F0001-0795; InChI=1/C9H9NS/c11-8-10-7-6-9-4-2-1-3-5-9/h1-5H,6-7H2

    Click to Show/Hide
Structure
Formula
C9H9NS
IUPAC Name
2-isothiocyanatoethylbenzene
Canonical SMILES
C1=CC=C(C=C1)CCN=C=S
InChI
InChI=1S/C9H9NS/c11-8-10-7-6-9-4-2-1-3-5-9/h1-5H,6-7H2
InChIKey
IZJDOKYDEWTZSO-UHFFFAOYSA-N
PubChem CID
16741
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 3 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Osteosarcoma ICD-11: 2B51
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Autophagy hsa04140
Cell Process Cell ferroptosis
Cell proliferation
Cell apoptosis
Cell autophagy
In Vitro Model K7M2-WT cells Osteosarcoma Mus musculus CVCL_V455
In Vivo Model
Male BALB/c mice, aged 4 weeks (14-16 g), were purchased from SPF (Beijing) Biotechnology Co., Ltd. K7M2 osteosarcoma cells were harvested and suspended in PBS at 4 . Mice were anesthetized with isoflurane. The left hindlimbs were shaved and cleaned with 75% ethanol. The knees of the mice were flexed beyond 90 and the cortex of the proximal tibial crest was penetrated using a 25 gauge needle by a rotating action. Once the tibial bone cortex was penetrated, the needles were further inserted 2 mm along the diaphysis, followed by injection of 10 uL of K7M2 osteosarcoma cells (5 x 105 cells) into the tibia.

    Click to Show/Hide
Response regulation Phenethyl isothiocyanate (PEITC) induces ferroptosis, autophagy, and apoptosis in K7M2 osteosarcoma cells by activating the ROS-related MAPK signaling pathway.
Experiment 2 Reporting the Ferroptosis-centered Drug Act on This Target [2]
Responsed Disease Osteosarcoma ICD-11: 2B51
 Disease Info 
Pathway Response Ferroptosis hsa04216
Apoptosis hsa04210
Autophagy hsa04140
Cell Process Cell ferroptosis
Cell apoptosis
Cell autophagy
Cell proliferation
In Vitro Model MNNG/HOS Cl #5 cells Osteosarcoma Homo sapiens CVCL_0439
U2OS cells Osteosarcoma Homo sapiens CVCL_0042
MG-63 cells Osteosarcoma Homo sapiens CVCL_0426
143B cells Osteosarcoma Homo sapiens CVCL_2270
Response regulation Phenethyl isothiocyanate (PEITC) reduced cell viability, inhibited proliferation, caused #REF!/M cell cycle arrest, altered iron metabolism, induced GSH depletion, generated ROS, activated MAPK signaling pathway, and triggered multiple cell death modalities, mainly ferroptosis, apoptosis, and autophagy, in human osteosarcoma cells.
Experiment 3 Reporting the Ferroptosis-centered Drug Act on This Target [3]
Responsed Disease Pancreatic cancer ICD-11: 2C10
 Disease Info 
Pathway Response Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model MIA PaCa-2 cells Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0428
PANC-1 cells Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0480
CFPAC-1 cells Pancreatic ductal adenocarcinoma Homo sapiens CVCL_1119
Response regulation The synergistic cell death induced by the combined treatment with Cotylenin A (CN-A) and phenethyl isothiocyanate (PEITC) is mainly due to the induction of ferroptosis. Therefore, the combination of CN-A and PEITC has potential as a novel therapeutic strategy against pancreatic cancer.
References
Ref 1 PEITC triggers multiple forms of cell death by GSH-iron-ROS regulation in K7M2 murine osteosarcoma cells. Acta Pharmacol Sin. 2020 Aug;41(8):1119-1132. doi: 10.1038/s41401-020-0376-8. Epub 2020 Mar 4.
Ref 2 -Phenethyl Isothiocyanate Induces Cell Death in Human Osteosarcoma through Altering Iron Metabolism, Disturbing the Redox Balance, and Activating the MAPK Signaling Pathway. Oxid Med Cell Longev. 2020 Apr 4;2020:5021983. doi: 10.1155/2020/5021983. eCollection 2020.
Ref 3 Combined treatment with cotyleninA and phenethyl isothiocyanate induces strong antitumor activity mainly through the induction of ferroptotic cell death in human pancreatic cancer cells. Oncol Rep. 2016 Aug;36(2):968-76. doi: 10.3892/or.2016.4867. Epub 2016 Jun 10.